We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04534582
Recruitment Status : Recruiting
First Posted : September 1, 2020
Last Update Posted : June 30, 2022
Information provided by (Responsible Party):
Shanghai Henlius Biotech

Brief Summary:

Part I of the study: This is a randomised, single-dose, subcutaneous injection, parallel study designed to compare the PK of HLX14 and EU-sourced Prolia® in healthy Chinese adult male subjects, and to assess the safety, tolerability, and immunogenicity of these 2 drugs.

Part II of the study: This is a randomised, double-blind, four-arm, single-dose, subcutaneous injection, parallel-controlled study to evaluate the PK, PD, safety, tolerability, and immunogenicity between-group following a single subcutaneous injection of HLX14 or US, EU, CN-sourced Prolia®.

Condition or disease Intervention/treatment Phase
Healthy Male Volunteers Drug: HLX14 Drug: EU-Prolia® Drug: US-Prolia® Drug: CN-Prolia® Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 228 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Parallel, Single-Dose, Subcutaneous Injection, Phase I Clinical Study Of HLX14 Versus Prolia® (Denosumab) In Chinese Healthy Adult Male Subjects For Comparison In Pharmacokinetic Characteristics, Safety, And Immunogenicity
Actual Study Start Date : November 3, 2020
Estimated Primary Completion Date : July 16, 2023
Estimated Study Completion Date : August 15, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Denosumab

Arm Intervention/treatment
Experimental: HLX14 group
HLX14 are given subcutaneous injection at a single dose of 60 mg.
Drug: HLX14
healthy volunteers receive HLX14 (60mg) once

Active Comparator: EU-Prolia® group
EU-Prolia® are given subcutaneous injection at a single dose of 60 mg.
Drug: EU-Prolia®
healthy volunteers receive EU-Prolia® (60mg) once

Active Comparator: US-Prolia® group
US-Prolia® are given subcutaneous injection at a single dose of 60 mg.
Drug: US-Prolia®
healthy volunteers receive US-Prolia® (60mg) once

Active Comparator: CN-Prolia® group
CN-Prolia® are given subcutaneous injection at a single dose of 60 mg.
Drug: CN-Prolia®
healthy volunteers receive CN-Prolia® (60mg) once

Primary Outcome Measures :
  1. AUC(0-t) [ Time Frame: from 0 to day 183 ]
    Area under the serum concentration-time curve from time 0 to the last concentration-quantifiable time t of denosumab

  2. Cmax [ Time Frame: from 0 to day 183 ]
    Maximum serum concentration following administration of denosumab

  3. AUC0-inf [ Time Frame: from 0 to day 183 ]
    Area under the serum concentration-time curve from time 0 to infinity

Secondary Outcome Measures :
  1. Tmax [ Time Frame: from 0 to day 183 ]
    Time to reach maximum serum concentration following administration

  2. CL/F [ Time Frame: from 0 to day 183 ]
    Total clearance

  3. λz [ Time Frame: from 0 to day 183 ]
    Apparent terminal elimination rate constant

  4. t1/2 [ Time Frame: from 0 to day 183 ]
    Elimination half life

  5. Vd/F [ Time Frame: from 0 to day 183 ]
    Apparent volume of distribution

  6. AUEC0-t [ Time Frame: from 0 to day 183 ]
    Area under the effect-time curve from time zero to last time of quantifiable concentration of Serum CTX1

  7. Imin [ Time Frame: from 0 to day 183 ]
    Minimum observed plasma concentration of Serum CTX1

  8. Imax [ Time Frame: from 0 to day 183 ]
    Maximum Percent Inhibition of Serum CTX1

  9. Tmin [ Time Frame: from 0 to day 183 ]
    Time to reach Imin of Serum CTX1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Males aged ≥ 18 and ≤ 65 years;
  2. Body weight ≥ 50 kg, body mass index (BMI) = body weight (kg)/body height2 (m2), BMI ≥ 19 and ≤ 26 kg/m2;
  3. With no disease history, or with abnormal prior medical history which has no effect on the trial as judged by the physician;
  4. Normal or abnormal without clinical significance in physical examination, vital signs, ECG, chest imaging, clinical laboratory test, etc.;
  5. Before the trial, sign the informed consent form (ICF) and have a full understanding of trial content, process, and possible adverse events (AEs); be able to complete the study as per protocol requirements.

Exclusion Criteria:

  1. With a history of allergy to study drugs, calcium, and/or vitamin D, or with a history of allergy to drugs or others not suitable for participating in this study as judged by the investigators;
  2. With the following clinically significant diseases (including but not limited to digestive system, kidney diseases, liver diseases, nervous diseases, blood system, endocrine system, tumor, respiratory system, immune diseases, mental diseases, or cardiovascular and cerebrovascular diseases);
  3. With a history of upper respiratory tract infection and other acute infections within 2 weeks prior to screening;
  4. Occurred or suffering from osteomyelitis or ONJ (Osteonecrosis of the jaw) previously. The dental or jaw disease that is active, requiring oral surgery; or dental or oral surgery wounds have not healed; or planned for invasive dental surgery during the study.
  5. With rash, scar, tattoo, etc. at administration site that may affect drug absorption;
  6. Blood donation or massive blood loss (> 450 mL) within 3 months prior to screening;
  7. Use of any prescription drugs, over-the-counter drugs, vitamin products, or traditional Chinese medicines within 28 days prior to screening;
  8. Participation in any drug clinical trials and use of any investigational/comparator drugs within 3 months prior to screening;
  9. Administration of drugs affecting bone metabolism within 6 months before participating in this study, including but not limited to: bisphosphonates, fluoride, calcitonin, strontium, parathyroid hormone or its derivatives, vitamin D supplements (> 1000 IU/day), glucocorticoids, anabolic steroids, calcitriol, and diuretics;
  10. Use of any biological products or monoclonal antibodies within 6 months prior to screening;
  11. With a history of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, 25 mL of spirit, or 100 mL of wine), or positive for alcohol breath test;
  12. With a history of substance abuse or drug abuse, or positive for drug screen;
  13. Positive for tobacco screen;
  14. With significant changes in physical activity within 6 months prior to screening, or not agree to abstain from strenuous physical exercise during the trial;
  15. Positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody;
  16. Abnormal serum calcium level (beyond the laboratory reference range) during the screening;
  17. Body temperature > 37.5 °C; and/or sitting systolic blood pressure (SBP) > 140 mmHg or < 90 mmHg, and/or diastolic blood pressure (DBP) > 90 mmHg or < 50 mmHg; and/or pulse rate > 100 beats/min or < 50 beats/min during the screening.
  18. Clinically significant abnormal ECG or QTcF > 450 ms during screening, or with a prior history of clinically significant abnormal ECG;
  19. Unwilling to take adequate contraceptive measures from screening to 6 months after the administration of study drugs. See Appendix 2 for specific contraceptive measures;
  20. Subjects who, in the opinion of the investigators, are not eligible to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04534582

Layout table for location contacts
Contact: Chaoming Ma, bachelor 0086-021-33395790 Chaoming_Ma@henlius.com

Layout table for location information
China, Shanghai
Huashan Hospital,Fudan University Recruiting
Shanghai, Shanghai, China, 200040
Contact: Jing Zhang, Doctor    0086-13816357098    13816357098@163.com   
Sponsors and Collaborators
Shanghai Henlius Biotech
Layout table for investigator information
Principal Investigator: Jing Zhang, Doctor Huashan Hospital
Publications of Results:
Layout table for additonal information
Responsible Party: Shanghai Henlius Biotech
ClinicalTrials.gov Identifier: NCT04534582    
Other Study ID Numbers: HLX14-001
First Posted: September 1, 2020    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Density Conservation Agents
Physiological Effects of Drugs